Skip to main content
GoodMoatv1.3
Sign in
PYXS logo

PYXS

CompareEarnings: May 31, 2026

Pyxis Oncology Inc

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next generation therapeutics that hold the potential for monotherapy and combination indications. PYX-201, an antibody-drug conjugate (ADC) that uniquely targets EDB+FN, a non-cellular structural component of the tumor extracellular matrix, is being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. Pyxis Oncology’s therapeutic candidates are designed to directly kill cancer cells and to address factors in the microenvironment that enable the uncontrolled proliferation and immune evasion of malignant tumors. Pyxis Oncology’s ADC and immuno-oncology (IO) programs employ novel and emerging strategies to target a broad range of solid tumors resistant or refractory to current standards of care.

Current Price

$2.74

+21.24%
Profile
Valuation (TTM)
Market Cap$170.60M
P/E-2.14
EV—
P/B3.19
Shares Out62.26M
P/Sales12.31
Revenue$13.86M
EV/EBITDA—

Pyxis Oncology Inc (PYXS) Company Profile

PYXS Company Information

Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers.

The company is efficiently building next generation therapeutics that hold the potential for monotherapy and combination indications.

PYX-201, an antibody-drug conjugate (ADC) that uniquely targets EDB+FN, a non-cellular structural component of the tumor extracellular matrix, is being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors.

Pyxis Oncology’s therapeutic candidates are designed to directly kill cancer cells and to address factors in the microenvironment that enable the uncontrolled proliferation and immune evasion of malignant tumors.

Pyxis Oncology’s ADC and immuno-oncology (IO) programs employ novel and emerging strategies to target a broad range of solid tumors resistant or refractory to current standards of care.

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

Massachusetts, USA

PYXS Key Officers

Key officers data coming soon

PYXS Company Profile

Pyxis Oncology Inc (PYXS) is a Healthcare company in the Biotechnology industry. It trades on NASDAQ. The company is based in Massachusetts, USA.

Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next generation therapeutics that hold the potential for monotherapy and combination indications. PYX-201, an antibody-drug conjugate (ADC) that uniquely targets EDB+FN, a non-cellular structural component of the tumor extracellular matrix, is being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. Pyxis Oncology’s therapeutic candidates are designed to directly kill cancer cells and to address factors in the microenvironment that enable the uncontrolled proliferation and immune evasion of malignant tumors. Pyxis Oncology’s ADC and immuno-oncology (IO) programs employ novel and emerging strategies to target a broad range of solid tumors resistant or refractory to current standards of care.

Market cap is $170.60M. There are 62.3M shares outstanding.

See the full Pyxis Oncology Inc profile on GoodMoat. It covers key officers, financial metrics, and sector details. You can also use GoodMoat's DCF calculator, fair value models, and quality score to help decide if PYXS is a good investment.